Početna stranicaLSI • FRA
add
CK Life Sciences Intl (Holdings) Inc
Preth. zaklj. cijena
0,090 €
Dnevni raspon
0,090 € - 0,090 €
Godišnji raspon
0,033 € - 0,091 €
Tržišna kapitalizacija
8,07 mlr. HKD
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
HKG
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (HKD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 1,44 mlr. | 5,22 % |
Operativni troškovi | 484,04 mil. | 31,22 % |
Neto dohodak | −63,78 mil. | −548,74 % |
Neto profitabilnost | −4,42 | −513,89 % |
Zarada po dionici | — | — |
EBITDA | 4,85 mil. | −95,35 % |
Efektivna porezna stopa | −32,21 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (HKD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 571,21 mil. | −15,52 % |
Ukupna imovina | 10,79 mlr. | −4,08 % |
Ukupne obveze | 7,28 mlr. | 3,10 % |
Ukupni kapital | 3,51 mlr. | — |
Dionice u optjecaju | 9,61 mlr. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,24 | — |
Povrat imovine | −0,87 % | — |
Povrat kapitala | −0,97 % | — |
Tok novca
Neto promjena novca
| (HKD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −63,78 mil. | −548,74 % |
Gotovina od poslovanja | 104,07 mil. | −52,01 % |
Gotovina iz ulaganja | −441,00 tis. | 98,29 % |
Gotovina iz financiranja | −93,26 mil. | 12,31 % |
Neto promjena novca | 2,38 mil. | −97,21 % |
Slobodan tok novca | 4,79 mil. | 136,38 % |
Više
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Mr. Victor Li, the elder son of Mr. Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
Glavni izvršni direktor
Osnovano
2000
Web-lokacija
Zaposlenici
2.033
